Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19

Authors:

Abstract
Purpose Autoantibodies (aAbs) to type I interferons (IFNs) have been found in less than 1% of individuals under the age of 60 in the general population, with the prevalence increasing among those over 65. Neutralizing autoantibodies (naAbs) to type I IFNs have been found in at least 15% of patients with life-threatening COVID-19 pneumonia in several cohorts of primarily European descent. We aimed to evaluate the prevalence of aAbs and naAbs to IFN-α2 or IFN-ω in Japanese patients who suffered from COVID-19 as well as in the general population. Methods Patients who suffered from COVID-19 (n = 622, aged 0–104) and an uninfected healthy control population (n = 3,456, aged 20–91) were enrolled in this study. The severities of the COVID-19 patients were as follows: critical (n = 170), severe (n = 235), moderate (n = 112), and mild (n = 105). ELISA and ISRE reporter assays were used to detect aAbs and naAbs to IFN-α2 and IFN-ω using E. coli-produced IFNs. Results In an uninfected general Japanese population aged 20–91, aAbs to IFNs were detected in 0.087% of individuals. By contrast, naAbs to type I IFNs (IFN-α2 and/or IFN-ω, 100 pg/mL) were detected in 10.6% of patients with critical infections, 2.6% of patients with severe infections, and 1% of patients with mild infections. The presence of naAbs to IFNs was significantly associated with critical disease (P = 0.0012), age over 50 (P = 0.0002), and male sex (P = 0.137). A significant but not strong correlation between aAbs and naAbs to IFN-α2 existed (r = − 0.307, p value < 0.0001) reinforced the importance of measuring naAbs in COVID-19 patients, including those of Japanese ancestry. Conclusion In this study, we revealed that patients with pre-existing naAbs have a much higher risk of life-threatening COVID-19 pneumonia in Japanese population.
Funding Information
  • Grants in Aid for Scientific Research from the Japan Society for the Promotion of Science (19H03620, JP19K07940, JP19K08908, 19HC1001, 21K19440)
  • Japan Agency for Medical Research and Development (JP20fk0108531, JP20fk0108453, 20fk0108104j0002)
  • Osaka City University Strategic Research Grant (OCU-SRG2021_YR09)
  • National Institutes of Health (R01AI088364, R01AI163029)
  • National Center for Advancing Translational Sciences (UL1 TR001866)
  • the French National Research Agency (ANR-10-IAHU-01)
  • the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID)
  • the French Foundation for Medical Research (EQU201903007798, FRM, EA20170638020)
  • ANR GENVIR (ANR-20-CE93-003)
  • ANR AABIFNCOV (ANR-20-CO11-0001)
  • ANR GenMISC (ANR-21-COVR-0039)
  • the European Union’s Horizon 2020 research and innovation programme under grant agreement (824110)
  • The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19)